Evidence map›Paper›PMID 31273298›Full record

ReviewSpinal cord2019

Neurochemical biomarkers in spinal cord injury.

Brian K Kwon, Ona Bloom, Ina-Beate Wanner, Armin Curt, Jan M Schwab, James Fawcett, Kevin K Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Spinal cord, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Exploring the Landscape of Biomarkers in Spinal Cord Injury.Topics in spinal cord injury rehabilitation · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brian K KwonInternational Collaboration on Repaid Discoveries, University of British Columbia, Vancouver, BC, Canada. brian.kwon@ubc.ca.
Ona BloomThe Feinstein Institute for Medical Research, Manhasset, NY, USA.ORCID http://orcid.org/0000-0002-8340-2392
Ina-Beate WannerSemel Institute for Neuroscience and Human Behavior, IDDRC, UCLA, Los Angeles, CA, USA.
Armin CurtUniversity Hospital Balgrist, University of Zürich, Zürich, Switzerland.
Jan M SchwabThe Belford Center for Spinal Cord Injury, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-6784-4919
James FawcettCambridge Center for Brain Repair, Cambridge, UK.
Kevin K WangProgram for Neurotrauma, Neuroproteomics & Biomarkers Research (NNBR), University of Florida, Gainesville, FL, USA.

Funding

Profiling human reactive astrocytes for neurotrauma biomarkersR21NS072606 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WANNER, INA BEATE · 2011 to 2012
$424k
Medical Research Council MR/R004544/1NINDS NIH HHS R21 NS072606
6 · The paper itself

Abstract

STUDY

designThis is a narrative review of the literature on neurochemical biomarkers in spinal cord injury (SCI).

objectivesThe objective was to summarize the literature on neurochemical biomarkers in SCI and describe their use in facilitating clinical trials for SCI. Clinical trials in spinal cord injury (SCI) have been notoriously difficult to conduct, as exemplified by the paucity of definitive prospective randomized trials that have been completed, to date. This is related to the relatively low incidence and the complexity and heterogeneity of the human SCI condition. Given the increasing number of promising approaches that are emerging from the laboratory which are vying for clinical evaluation, novel strategies to help facilitate clinical trials are needed.

methodsA literature review was conducted, with a focus on neurochemical biomarkers that have been described in human neurotrauma.

resultsWe describe advances in our understanding of neurochemical biomarkers as they pertain to human SCI. The application of biomarkers from serum and cerebrospinal fluid (CSF) has been led by efforts in the human traumatic brain injury (TBI) literature. A number of promising biomarkers have been described in human SCI whereby they may assist in stratifying injury severity and predicting outcome.

conclusionsSeveral time-specific biomarkers have been described for acute SCI and for chronic SCI. These appear promising for stratifying injury severity and potentially predicting outcome. The subsequent application within a clinical trial will help to demonstrate their utility in facilitating the study of novel approaches for SCI.

Indexed as

BiomarkersHumansPrognosisRecovery of FunctionSpinal Cord InjuriesBiomarkers

Identifiers

PMID31273298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.